Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report
We present two cases of minors with TS who started CBM treatment at the age of eight and 12 years, respectively, and continued treatment for five to six years resulting in clinically relevant symptom improvement without any severe adverse effects or negative impact on cognitive and academic performance.
Authors
- Simon Schmitt (ORCID: https://orcid.org/0000-0003-4004-0587)
- Natalia Szejko (ORCID: https://orcid.org/0000-0001-6160-9221)
- Carolin Fremer (ORCID: https://orcid.org/0000-0002-9585-7415)
- Lara-Katharina Woerner
- Kirsten R. Müller Vahl
Institutions
- Medical University of Warsaw (PL)
- Medizinische Hochschule Hannover (DE)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3389/fpsyt.2025.1647969
- Citations
- 2
- Primary Topic
- Obsessive-Compulsive Spectrum Disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.61
Funders
- American Brain Foundation
- Alexion Pharmaceuticals
- Tourette Association of America
- GW Pharmaceuticals
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Warszawski Uniwersytet Medyczny
- Uniwersytet Warszawski
- EVER Neuro Pharma
- H. Lundbeck A/S
- Neuraxpharm
- Ministerstwo Zdrowia
- National Institute of Mental Health
- FP7 People: Marie-Curie Actions
- FP7 Health